Literature DB >> 15519483

Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients.

M Koldehoff1, J L Zakrzewski.   

Abstract

Taurolidine is an antimicrobial agent that was originally used in the local treatment of peritonitis and was shown to be effective in the prevention of catheter-related bloodstream infections (CR-BSI). In this pilot study, we used taurolidine solution as an intravenous (i.v.) lock into the totally implantable intravascular devices of 11 consecutive oncological patients with catheter-related bloodstream infections not responding to systemic antimicrobial chemotherapy. All patients recovered completely from the infection. No adverse drug effects were seen. Three patients were successfully retreated for a recurrent infection. Our data suggest a beneficial role of taurolidine i.v. lock for the therapy of catheter-related bloodstream infections in oncological patients. Taurolidine i.v. lock application is feasible and could especially be useful in infections resistant to antibiotic chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15519483     DOI: 10.1016/j.ijantimicag.2004.06.006

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  15 in total

1.  Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines.

Authors:  Ansgar M Chromik; Adrien Daigeler; Daniel Bulut; Annegret Flier; Christina May; Kamran Harati; Jan Roschinsky; Dominique Sülberg; Peter R Ritter; Ulrich Mittelkötter; Stephan A Hahn; Waldemar Uhl
Journal:  J Exp Clin Cancer Res       Date:  2010-03-07

2.  Taurolidine as an effective and biocompatible additive for plaque-removing techniques on implant surfaces.

Authors:  Gordon John; Frank Schwarz; Jürgen Becker
Journal:  Clin Oral Investig       Date:  2014-10-28       Impact factor: 3.573

3.  Autophagy induced by taurolidine protects against polymicrobial sepsis by promoting both host resistance and disease tolerance.

Authors:  Jie Huang; Michael Ita; Huiting Zhou; He Zhao; Fara Hassan; Zhenjiang Bai; D Peter O'Leary; Yiping Li; H Paul Redmond; Jiang Huai Wang; Jian Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-05       Impact factor: 12.779

4.  Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm.

Authors:  Issam Raad; Hend Hanna; Tanya Dvorak; Gassan Chaiban; Ray Hachem
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

5.  Taurolidine antiadhesive properties on interaction with E. coli; its transformation in biological environment and interaction with bacteria cell wall.

Authors:  Francesco Caruso; James W Darnowski; Cristian Opazo; Alexander Goldberg; Nina Kishore; Elin S Agoston; Miriam Rossi
Journal:  PLoS One       Date:  2010-01-28       Impact factor: 3.240

6.  Oral administration of the anti-proliferative substance taurolidine has no impact on dextran sulfate sodium induced colitis-associated carcinogenesis in mice.

Authors:  Ansgar Michael Chromik; Sebastian Huss; Hayssam Osseili; Adrien Daigeler; Sabine Kersting; Dominique Sülberg; Ulrich Mittelkötter; Thomas Herdegen; Waldemar Uhl; Annette M Müller
Journal:  J Carcinog       Date:  2010-04-16

7.  Taurolidine induces epithelial-mesenchymal transition via up-regulation of the transcription factor Snail in human pancreatic cancer cell lines.

Authors:  Birgit Hotz; Ulrike Erben; Marco Arndt; Heinz J Buhr; Hubert G Hotz
Journal:  Int J Colorectal Dis       Date:  2014-09-03       Impact factor: 2.571

8.  Gene expression analysis of cell death induction by taurolidine in different malignant cell lines.

Authors:  Ansgar M Chromik; Stephan A Hahn; Adrien Daigeler; Annegret Flier; Daniel Bulut; Christina May; Kamran Harati; Jan Roschinsky; Dominique Sülberg; Dirk Weyhe; Ulrich Mittelkötter; Waldemar Uhl
Journal:  BMC Cancer       Date:  2010-10-30       Impact factor: 4.430

9.  Central venous catheter-associated Nocardia bacteremia in cancer patients.

Authors:  Fadi Al Akhrass; Ray Hachem; Jamal A Mohamed; Jeffrey Tarrand; Dimitrios P Kontoyiannis; Jyotsna Chandra; Mahmoud Ghannoum; Souha Haydoura; Ann Marie Chaftari; Issam Raad
Journal:  Emerg Infect Dis       Date:  2011-09       Impact factor: 6.883

10.  Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients.

Authors:  Arne Simon; Roland A Ammann; Gertrud Wiszniewsky; Udo Bode; Gudrun Fleischhack; Mette M Besuden
Journal:  BMC Infect Dis       Date:  2008-07-29       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.